Enara Bio Ltd, a UK biotech, has raised $32.5 million in Series B financing to build a pipeline of therapies for cancer that target peptide antigens in the dark genome. The financing round was co-led by the new investors Pfizer Ventures and M Ventures whose executives, respectively, Rana Al-Hallaq and Bauke Anninga, have joined the company’s board of directors.
